Global Neprilysin Market Size By Type (TD-0714, STR-324), By Application (Acute Heart Failure, Cancer Pain), By Region, And Segment Forecasts, 2023 to 2032

The Global Neprilysin Market was valued at USD 1.3 billion in 2023 and is anticipated to reach USD 2.7 billion by 2031, growing at a CAGR of 9.6% during the forecast period of 2023 to 2031. Neprilysin, a key enzyme involved in the degradation of several vasoactive peptides, has garnered substantial attention due to its role in cardiovascular disease, Alzheimer’s disease, and cancer. The growing prevalence of chronic cardiovascular and neurodegenerative disorders, coupled with ongoing pharmaceutical research into neprilysin inhibitors and combination therapies, is significantly propelling the global market.

Drivers:

Rising Prevalence of Cardiovascular Disorders:

The global surge in heart failure cases is a primary factor boosting the demand for neprilysin inhibitors such as sacubitril. These inhibitors play a vital role in managing heart failure with reduced ejection fraction (HFrEF), enhancing therapeutic outcomes when combined with angiotensin receptor blockers.

Growing Geriatric Population:

An aging global population is more susceptible to both cardiovascular and neurodegenerative diseases. Neprilysin’s involvement in amyloid-beta peptide degradation makes it a therapeutic target for Alzheimer's disease, further driving market demand.

Ongoing Drug Development Initiatives:

The pharmaceutical industry is heavily investing in R&D to develop novel neprilysin inhibitors. Several clinical trials are underway, aiming to expand indications and improve efficacy, which is expected to fuel market growth.

Restraints:

Adverse Effects and Safety Concerns:

Combination therapies involving neprilysin inhibitors have shown some adverse effects such as hypotension and angioedema, limiting their acceptance in certain patient populations.

High Treatment Costs:

Innovative drug therapies targeting neprilysin are often priced at a premium, which can hinder accessibility, especially in low-income regions with underdeveloped healthcare infrastructure.

Opportunity:

Expansion into Neurodegenerative Disorder Treatments:

Neprilysin's role in degrading amyloid-beta has made it a promising target for Alzheimer's treatment. With rising investments in neurological R&D, the potential use of neprilysin modulators in this domain offers vast untapped market potential.

Partnerships and Strategic Collaborations:

Biopharmaceutical companies are increasingly entering into strategic alliances to co-develop neprilysin-targeting therapies, facilitating broader global reach and accelerated commercialization.

Market by System Type Insights:

Based on system type, Neprilysin Inhibitor Drugs held the largest share in 2023, predominantly driven by the success of sacubitril/valsartan combinations. This segment is expected to continue its dominance due to established efficacy in cardiovascular therapy. However, the Gene Therapy and Monoclonal Antibody segments are projected to grow at a faster rate, supported by breakthroughs in precision medicine.

Market by End-use Insights:

Hospitals emerged as the leading end-use segment in 2023, driven by the growing number of cardiovascular admissions and treatment procedures involving neprilysin inhibitors. Research Institutions are also expected to witness significant growth owing to the expansion of clinical trials for neurodegenerative and oncology applications.

Market by Regional Insights:

North America led the global neprilysin market in 2023, owing to strong healthcare infrastructure, advanced R&D capabilities, and the presence of major pharmaceutical players. Asia-Pacific is projected to record the highest CAGR through 2031 due to rising healthcare investments, increased disease burden, and rapid adoption of advanced therapeutics in emerging economies such as China and India.

Competitive Scenario:

Key players operating in the Global Neprilysin Market include:

Novartis AG

AstraZeneca

Amgen Inc.

Bristol-Myers Squibb

Johnson & Johnson

Pfizer Inc.

Teva Pharmaceutical Industries Ltd.

Merck & Co., Inc.

Bayer AG

Daiichi Sankyo Co., Ltd.

These companies are focusing on clinical trial advancements, FDA approvals, and strategic partnerships to strengthen their positions. For instance:

In 2023, Novartis received extended FDA approval for Entresto (sacubitril/valsartan) to cover additional cardiovascular conditions.

In 2024, AstraZeneca launched a collaborative study with academic institutions to explore neprilysin's role in Alzheimer's therapy.

Scope of Work – Global Neprilysin Market

Report Metric Details

Market Size (2023) USD 1.3 Billion

Projected Market Size (2031) USD 2.7 Billion

CAGR (2023–2031) 9.6%

Market Segments System Type, End-use, Region

Growth Drivers Cardiovascular disease prevalence, drug development initiatives

Opportunities Alzheimer’s treatment potential, global collaborations

Key Market Developments:

2023: Novartis announced expanded clinical trial results for its neprilysin inhibitor combination therapy, showing enhanced survival rates in patients with heart failure.

2024: Pfizer initiated Phase II trials of its novel neprilysin-targeting therapy aimed at early-stage Alzheimer’s patients.

2025: Amgen entered into a co-development agreement with a biotech firm to explore gene-editing approaches targeting neprilysin expression.

FAQs:

What is the current market size of the Global Neprilysin Market?

The market size was valued at USD 1.3 billion in 2023.

What is the major growth driver of the Global Neprilysin Market?

Rising prevalence of cardiovascular diseases and increasing adoption of neprilysin inhibitors.

Which is the largest region during the forecast period in the Global Neprilysin Market?

North America held the largest market share in 2023.

Which segment accounted for the largest market share in the Global Neprilysin Market?

Neprilysin Inhibitor Drugs segment led the market in 2023.

Who are the key market players in the Global Neprilysin Market?

Novartis AG, AstraZeneca, Pfizer, Amgen Inc., Bayer AG, and others.